Dr Minal Dalvi received her PhD in Immunology and Microbiology from University of Arizona (USA). Her doctoral dissertation assessed the role of genetic and environmental factors in the development of asthma and allergy.
She then worked as a post-doctoral research fellow at New York University (USA) and was involved in a proteomics project assessing immune protein expression in HIV-infected individuals pre- and post- HAART treatment. Dr Dalvi also studied the role of an oral bacteria, P. gingivalis, in development of oral cancer at NYU.
Her interest in bringing new treatments from bench to bedside led her to pursue a master’s degree in Intellectual Property Law at University of Technology, Sydney. Dr Dalvi worked as the Director of Research at The Skin Hospital, a not-for-profit dermatology hospital. She has extensive experience in running Phase 2 and Phase 3 clinical trials. In her current role at the Kirby Institute, Dr Dalvi is overseeing the BRIDGE program, which aims at advancing the development of RNA therapeutics.